Department of Therapeutics and Pharmacology, The Queen's University, Belfast.
Br J Clin Pharmacol. 1974 Aug;1(4):291-4. doi: 10.1111/j.1365-2125.1974.tb00255.x.
1 A double blind cross-over study was carried out on patients with reversible airways disease attending an out-patient clinic. 2 Twenty patients were given either salbutamol (200 μg) or propellant by aerosol for two week periods and in another study twelve patients were given identical tablets containing either salbutamol (4 mg) or placebo for four week periods. Both forms of therapy were taken four times per day but stopped the evening before attending the clinic. 3 The improvement in FEV(1) 10 min following salbutamol (200 μg) by aerosol was measured after previous treatment with either salbutamol or placebo administered by aerosol and orally and the results were compared statistically. This failed to show a significant difference and suggests that regular treatment with salbutamol does not lead to a decreased response.
一项针对在门诊就诊的可逆转气道疾病患者的双盲交叉研究。
20 名患者接受沙丁胺醇(200μg)或气雾剂推进剂治疗两周,在另一项研究中,12 名患者接受含有沙丁胺醇(4mg)或安慰剂的相同片剂治疗四周。两种形式的治疗均每天四次,但在就诊前一天晚上停止。
在先前使用沙丁胺醇或安慰剂气雾剂和口服治疗后,测量了沙丁胺醇(200μg)气雾剂治疗后 10 分钟内 FEV(1)的改善情况,并进行了统计学比较。这未能显示出显著差异,表明常规使用沙丁胺醇不会导致反应减弱。